Antoinette van Weverwijk has been announced as the 2025 recipient of an EACR-AstraZeneca Postdoctoral Fellowship, funding that is awarded for a period of up to three years to support excellent postdoctoral researchers in laboratories throughout Europe and the world.
Jane Smith, Chief Executive Officer at the EACR, says, “Congratulations to Antoinette on her Fellowship. We look forward to hearing her talk at the EACR 2025 Congress in Lisbon, and to following her research progress over the next three years. We are grateful to AstraZeneca for their support for EACR members.”
Having recently begun her Fellowship, Antoinette let us know how she feels about receiving this funding, “I am very grateful to have been awarded the prestigious EACR-AstraZeneca Postdoctoral Fellowship. This Fellowship will give me the opportunity to further develop my project at the interface of industry and academia, and will provide a unique opportunity to initiate the translation of a basic research project towards the clinic. I very much look forward to presenting my work at the EACR Congress in June and start this exciting collaboration with scientists at AstraZeneca.”
About the Recipient
Antoinette van Weverwijk is a senior postdoctoral research fellow in the group of Prof. Karin de Visser at the Netherlands Cancer Institute (NKI) in Amsterdam. After completing her bachelor degree in the Netherlands, she moved to the UK for a MSc program in Human Molecular Genetics at Imperial College, London. For her PhD studies she joined the group of Prof. Clare Isacke at the Institute of Cancer Research (ICR) in London, where she focused on identifying novel drivers of breast cancer metastasis and modulators of chemotherapy response.
Antoinette current research is focused on understanding the impact of key genetic drivers on the composition and function of the immune landscape in breast tumourigenesis. To elucidate how common genetic aberrations in breast cancer cells affect the communication and interaction with the immune system, she combines mechanistic studies and therapeutic interventions in genetically engineered mouse models (GEMMs) of breast cancer. Her overall goal is to gain novel molecular insights into tumour genotype/immune phenotype relationships in breast cancer, and identify new avenues for the development of tailored immunomodulatory strategies for breast cancer patients.
Click here to see Antoinette van Weverwijk’s institute profile page
Connect with Antoinette on LinkedIn and Bluesky
NKI’s social links: Instagram, LinkedIn and Bluesky
More about EACR-AstraZeneca Postdoctoral Fellowships
The aims of this funding are to support the career development of outstanding EACR members in the early stage of their careers, and to train the next generation of scientists engaged in innovative research in areas where AstraZeneca has demonstrated leadership through its pipeline and research programs. Learn more here.
